SPX4,297.14+16.99 0.40%
DIA339.37+1.54 0.46%
IXIC13,128.05+80.87 0.62%

BRIEF-Alnylam Pharmaceuticals Reports Q2 Net Loss of $2.29 Per Share

BRIEF-Alnylam Pharmaceuticals Reports Q2 Net Loss of $2.29 Per Share

Reuters · 07/28/2022 08:16
BRIEF-Alnylam Pharmaceuticals Reports Q2 Net Loss of $2.29 Per Share

- Alnylam Pharmaceuticals Inc ALNY:

  • ALNYLAM PHARMACEUTICALS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PERIOD ACTIVITY

  • QTRLY NET PRODUCT REVENUES OF $214 MILLION FOR ONPATTRO, GIVLAARI, AND OXLUMO (33% GROWTH VERSUS. SAME PERIOD LAST YEAR)

  • ALNYLAM PHARMACEUTICALS - RECEIVED FDA APPROVAL OF AMVUTTRA FOR TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS

  • REITERATED 2022 FINANCIAL GUIDANCE

  • QTRLY GAAP NET LOSS PER COMMON SHARE - BASIC AND DILUTED$2.29

  • QTRLY NON-GAAP NET LOSS PER COMMON SHARE - BASIC AND DILUTED $2.03

  • Q2 EARNINGS PER SHARE VIEW $-1.63, REVENUE VIEW $255.9 MILLION -- REFINITIV IBES DATA

  • FY2022 EARNINGS PER SHARE VIEW $-6.82, REVENUE VIEW $1.09 BILLION -- REFINITIV IBES DATA

Source text for Eikon: ID:

Further company coverage: ALNY


((Reuters.Briefs@thomsonreuters.com;))